HIPEC has great potential for the future
Once a recurrence in the peritoneal cavity is diagnosed, the disease is no longer considered curable and the median rate of progression-free survival is 6-9 months. For this reason, prevention of disease progression and improvement of treatment methods are of utmost significance. At present, various research centers are studying the role of HIPEC in the treatment of ovarian cancer through well-designed clinical trials. These clinical trials will further explore the safety and effectiveness of HIPEC treatment, as well as which patient groups are most likely to benefit from the treatment without added toxicity. In turn, the results gathered may have on impact on how patients with advanced ovarian cancer are treated in the coming years.